Description
The OV56 cell line was established from ascitic fluid derived from a 46-year-old female patient diagnosed with ovarian cancer. The tumour was characterised as stage IV, poorly differentiated. Immunocytochemical staining of the cells was reported to show strong staining for cytokeratin (CK), weak staining for carcinoembryonic antigen (CEA) and strong staining for human milk fat globulin (HMFG-2). Production of vascular endothelial growth factor (VEGF) has been detected by ELISA. The patient had received sequential treatment with cisplatin and cyclophosphamide, cisplatin and etoposide and subsequently tamoxifen.
Adherent Suspension
Adherent
Suggested Medium
DMEMHAMS F12 (11) + 2mM Glutamine + 5% Foetal Bovine Serum (FBS) + 0.5 ug/ml hydrocortisone + 10ug/ml insulin
Quality Control
OV56 Cell Line was tested and found to be free of mycoplasma, bacterial, viruses, and other toxins. All cells were above 95% viability before freezing.
Shippment
OV56 Cell Line will be shipped using dry ice.
Storage
Store the cell lines in liquid nitrogen vapor (less than -130°C)
Warranty
OV56 Cell Line is for research use only
